Mokhtari M, Sargazi S, Saravani R, Heidari Nia M, Mirinejad S, Hadzsiev K
Dis Markers. 2022; 2022:1886658.
PMID: 36193501
PMC: 9526595.
DOI: 10.1155/2022/1886658.
Umapathy V, Natarajan P, Swamikannu B, Moses J, Jones S, Chandran M
Biosensors (Basel). 2022; 12(7).
PMID: 35884301
PMC: 9312890.
DOI: 10.3390/bios12070498.
Lin P, Sun J, Lou X, Li D, Shi Y, Li Z
Gen Psychiatr. 2022; 35(1):e100685.
PMID: 35309241
PMC: 8867318.
DOI: 10.1136/gpsych-2021-100685.
Goldoni R, Scolaro A, Boccalari E, Dolci C, Scarano A, Inchingolo F
Biosensors (Basel). 2021; 11(10).
PMID: 34677352
PMC: 8533918.
DOI: 10.3390/bios11100396.
Ghafouri-Fard S, Eghtedarian R, Taheri M, Bruhl A, Sadeghi-Bahmani D, Brand S
Front Psychiatry. 2021; 12:640463.
PMID: 34220567
PMC: 8249727.
DOI: 10.3389/fpsyt.2021.640463.
Sex-Specific Associations of Polymorphisms With Schizophrenia in a Han Chinese Cohort.
Yin J, Luo X, Peng Q, Xiong S, Lv D, Dai Z
Front Genet. 2021; 12:627874.
PMID: 33708240
PMC: 7942225.
DOI: 10.3389/fgene.2021.627874.
The MIR137 VNTR rs58335419 Is Associated With Cognitive Impairment in Schizophrenia and Altered Cortical Morphology.
Mahmoudi E, Atkins J, Quide Y, Reay W, Cairns H, Fitzsimmons C
Schizophr Bull. 2020; 47(2):495-504.
PMID: 32910167
PMC: 8370045.
DOI: 10.1093/schbul/sbaa123.
Two Thalamic Regions Screened Using Laser Capture Microdissection with Whole Human Genome Microarray in Schizophrenia Postmortem Samples.
Bakshi K, Kemether E
Schizophr Res Treatment. 2020; 2020:5176834.
PMID: 32566292
PMC: 7285254.
DOI: 10.1155/2020/5176834.
Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development.
Howell K, Law A
Schizophr Res. 2019; 217:95-104.
PMID: 31522868
PMC: 7065975.
DOI: 10.1016/j.schres.2019.08.036.
The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia.
Rammos A, Gonzalez L, Weinberger D, Mitchell K, Nicodemus K
Neuropsychopharmacology. 2019; 44(9):1562-1569.
PMID: 31078131
PMC: 6785707.
DOI: 10.1038/s41386-019-0410-z.
microRNAs Sculpt Neuronal Communication in a Tight Balance That Is Lost in Neurological Disease.
Thomas K, Gross C, Bassell G
Front Mol Neurosci. 2019; 11:455.
PMID: 30618607
PMC: 6299112.
DOI: 10.3389/fnmol.2018.00455.
Polymorphism in schizophrenia risk gene is associated with the posterior cingulate Cortex's activation and functional and structural connectivity in healthy controls.
Zhang Z, Yan T, Wang Y, Zhang Q, Zhao W, Chen X
Neuroimage Clin. 2018; 19:160-166.
PMID: 30035013
PMC: 6051762.
DOI: 10.1016/j.nicl.2018.03.039.
Dysregulation of miRNA and its potential therapeutic application in schizophrenia.
Cao T, Zhen X
CNS Neurosci Ther. 2018; 24(7):586-597.
PMID: 29529357
PMC: 6490029.
DOI: 10.1111/cns.12840.
A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia.
Sakamoto K, Crowley J
Am J Med Genet B Neuropsychiatr Genet. 2018; 177(2):242-256.
PMID: 29442441
PMC: 5815396.
DOI: 10.1002/ajmg.b.32554.
MiRNAs of peripheral blood as the biomarker of schizophrenia.
He K, Guo C, He L, Shi Y
Hereditas. 2017; 155:9.
PMID: 28860957
PMC: 5575894.
DOI: 10.1186/s41065-017-0044-2.
MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls.
Cosgrove D, Harold D, Mothersill O, Anney R, Hill M, Bray N
Transl Psychiatry. 2017; 7(1):e1012.
PMID: 28117840
PMC: 5545742.
DOI: 10.1038/tp.2016.286.
MicroRNA-137 Inhibits EFNB2 Expression Affected by a Genetic Variant and Is Expressed Aberrantly in Peripheral Blood of Schizophrenia Patients.
Wu S, Zhang R, Nie F, Wang X, Jiang C, Liu M
EBioMedicine. 2016; 12:133-142.
PMID: 27650867
PMC: 5078603.
DOI: 10.1016/j.ebiom.2016.09.012.
MiR-137: an important player in neural development and neoplastic transformation.
Mahmoudi E, Cairns M
Mol Psychiatry. 2016; 22(1):44-55.
PMID: 27620842
PMC: 5414082.
DOI: 10.1038/mp.2016.150.
Identification and Potential Regulatory Properties of Evolutionary Conserved Regions (ECRs) at the Schizophrenia-Associated MIR137 Locus.
Gianfrancesco O, Griffiths D, Myers P, Collier D, Bubb V, Quinn J
J Mol Neurosci. 2016; 60(2):239-47.
PMID: 27525637
PMC: 5026716.
DOI: 10.1007/s12031-016-0812-x.
MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?.
Nadim W, Simion V, Benedetti H, Pichon C, Baril P, Morisset-Lopez S
Curr Neuropharmacol. 2016; 15(2):260-275.
PMID: 27396304
PMC: 5412695.
DOI: 10.2174/1570159x14666160709001441.